GuruFocus DCF Values NVO at $91 vs $46, but Core Thesis Remains Cautious

What happened

On August 17, 2026, GuruFocus published a DCF analysis suggesting Novo Nordisk's intrinsic value is $91 per share, nearly double its recent price of $46, implying deep undervaluation. This contrasts with the current DeepValue master report, which holds a more cautious "POTENTIAL BUY" rating with a conviction of 3.5 and a base-case value of $52, driven by ongoing U.S. pricing pressure and the need for oral Wegovy to convert demand into reimbursed volume. The DCF likely assumes stronger long-term pricing or faster market expansion than what recent filings support, as Novo's own guidance for 2026 projects adjusted sales growth of 0% to -6% due to lower realized prices. The master report highlights that while oral Wegovy has generated over 5 million prescriptions and 265,000 weekly U.S. prescriptions, injectable Wegovy sales fell 22% in Q2, and H1 U.S. operations declined 4% at constant exchange rates. Despite the optimistic DCF, the stock closed at $47.26 on August 7, 2026, near the master report's current price of $47.3, suggesting the market has not yet bought into the $91 intrinsic value thesis.

Implication

Near-term, the stock may see limited upside until the September 21 Capital Markets Day clarifies 2027 access economics and gross-to-net trends. If management can demonstrate conversion of oral Wegovy prescriptions into insured coverage and stable realized prices, the stock could re-rate toward the bull case of $59, but not $91, given the structural pricing headwinds. Conversely, if oral demand plateaus or pricing continues to erode, the bear case of $40 becomes more likely. The DCF's $91 intrinsic value should be heavily discounted because it likely fails to account for the reality of rebates and competition in the U.S. obesity market. Investors should monitor weekly prescription trends, Medicare Bridge enrollment, and the CagriSema FDA decision before adding to positions.

Thesis delta

The new DCF article does not alter the deep value thesis, which already incorporates significant upside relative to the market price but at a lower magnitude. The master report's base case of $52 remains the central expectation, while the DCF's $91 serves as an upper bound only if pricing power is restored, which is not currently evidenced. Therefore, the thesis remains unchanged: potential buy with conviction 3.5, attractive entry near $44, trim above $56.